阿司匹林敏感性:对冠状动脉疾病患者的影响
Raghava R Gollapudi1, Paul S Teirstein, Donald D Stevenson
1Divison of Cardiovascular Diseases, Scripps Clinic and the Scripps Research Institute, La Jolla, Calif 92037, USA.
JAMA
|December 23, 2004
概括
乙盐酸 (阿司匹林) 敏感性很常见,通常会引起呼吸道或皮肤反应. 脱敏对许多人来说是安全的,但对于冠状动脉疾病 (CAD) 患者需要更多的研究.
科学领域:
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 乙盐酸 (阿司匹林) 被广泛用于慢性心血管疾病.
- 少数患者对阿司匹林和其他NSAIDs表现出敏感性.
- 阿司匹林敏感性可以表现为呼吸系统问题或疹.
研究的目的:
- 概述阿司匹林敏感性的诊断策略.
- 为阿司匹林敏感患者提供治疗指南,特别是那些患有冠状动脉疾病 (CAD) 的患者.
主要方法:
- 在MEDLINE和Cochrane数据库 (1966-2004) 中进行文献搜索.
- 包括受控,英语,同行评审的研究.
- 从获取的文章中查看参考文献的审查.
主要成果:
- 阿司匹林加剧的呼吸系统疾病影响到~10%的人口;阿司匹林诱导的疹影响到0.07-0.2%.
- 敏感性主要是由于循环氧化原酶-1 抑制,很少 IgE 介导.
- 大多数患者可以成功地接受阿司匹林脱敏治疗,但慢性异常性疹患者除外.
结论:
- 阿司匹林敏感性很普遍,降解敏感性通常是安全有效的.
- 由于目前的数据有限,进一步的大规模试验至关重要,以确认在CAD患者中阿司匹林脱敏的安全性和有效性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...


